Lifestyle Therapeutics in Obesity Medicine Certificate Program
|
The AAP has comprehensively updated their recommendations regarding the disease of obesity in childhood. The incidence of obesity in childhood has not improved.
|
Recent AAP obesity guidelines point out that "watchful waiting" can delay treatment.
|
Obesity pharmacotherapy often is solely equated as therapeutic use of anti-obesity medications (AOMs). In this session, two important factors in obesity pharmacotherapy will be discussed.
|
This webinar will discuss the latest advances in the management of the pre/post Bariatric patient After attending this webinar, the participants will be able to describe the latest recommendations
|
This talk will review key features of obesity pathogenesis related to genetics, the brain, and energetics.
|
This session will review the relationship and underlying mechanisms between obesity and cardiovascular disease with attention to the individual variability between BMI and CV risk.
|
OMA 2023 Spring Summit: Nutrition Rx for Management of Obesity (On Demand)CME/CE Expiration Date: 4/23/26
|
The body mass index (BMI) is the most commonly used screening tool for obesity. However, the BMI is a population-based tool with several limitations when applied to individuals.
|
This session will examine the use of on-label anti-obesity pharmacotherapy to treat obesity.
|